頭痛講演 2月25日、28日
投稿
Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, et al. Brain Behav. 2022;12(3):e2526.
Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, et al. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies. Brain Behav. 2022;12(3):e2526. https://www.ncbi.nlm.nih.gov/pubmed/35201674 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933787/pdf/BRB3-12-e2526.pdf 2022/02/25
Takeshima T, , et al. J Headache Pain. 2022;23(1):24.
Takeshima T , Nakai M, Shibasaki Y, Ishida M, Kim BK, Ning X, et al. Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients. J Headache Pain. 2022;23(1):24. https://www.ncbi.nlm.nih.gov/pubmed/35139816 2022/02/11
Takahashi M, Shimokawa T, Koh J, Takeshima T, Yamashita H, Kajimoto Y, et al. J Neurol Sci. 2022;432:120078.
Takahashi M, Shimokawa T, Koh J, Takeshima T, Yamashita H, Kajimoto Y, et al. Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan. J Neurol Sci. 2022;432:120078. https://www.ncbi.nlm.nih.gov/pubmed/34923334 2021/12/20